奥萨尔米德通过STAT3/BCL-XL通路使清细胞细胞癌对纳维托克拉克斯敏感
Yizheng Xue1, Tianyi Chen2, Zehua Ma3
1Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Cancer letters
|February 2, 2025
概括
结合奥萨尔米德和纳维托克拉克斯的新治疗策略在治疗清细胞细胞癌 (ccRCC) 方面表现有前途. 这种方法诱导瘤细胞衰老和亡,为ccRCC治疗提供了一个新的途径.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 药物发现 药物发现 药物发现
背景情况:
- 清细胞细胞癌 (ccRCC) 是一种致命的癌症,由于对亡的抗性,治疗结果不佳.
- 诱导瘤细胞衰老,其次是老化药物是一种潜在的癌症治疗策略.
- 这种策略在ccRCC中的有效性在很大程度上仍未被探索.
研究的目的:
- 为了确定用于ccRCC治疗的向基因.
- 评估一种新的治疗方法,将osalmid和navitoclax结合用于ccRCC.
- 阐明这种组合治疗的潜在机制.
主要方法:
- 利用依赖地图 (DepMap) 门户进行全基因组CRISPR查,以识别ccRCC中的基本基因.
- 在各种ccRCC临床前模型中测试了osalmid (RRM2抑制剂) 和navitoclax (BCL-XL抑制剂) 的组合.
- 研究了包括dNTP生成,衰老诱导,STAT3激活和BCL-XL/BCL-2家族蛋白质表达在内的机制性途径.
主要成果:
- 在ccRCC中,核酸减少酶子单元2 (RRM2) 被确定为一个关键的向基因.
- 奥萨尔米德和纳维托克拉克斯的组合在各种ccRCC细胞系,异种移植 (CDX,PDX) 和有机物 (PDO) 中显示出有效性.
- 奥萨米尔德通过抑制dNTP合成来诱导ccRCC细胞衰老,导致STAT3激活和BCL-XL增加,使细胞对纳维托克拉克斯敏感.
结论:
- 奥萨尔米德和纳维托克拉克斯的组合代表了ccRCC的新和有效的治疗策略.
- 用胺针对RRM2来诱导衰老和随后的BCL-XL上调,创造了一个可被navitoclax利用的漏洞.
- 这种方法具有显著的潜力,可以改善ccRCC患者的治疗结果.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K


